{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:57:52Z","timestamp":1776959872455,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hemolytic uremic syndrome (HUS), characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury (AKI), remains a leading cause of pediatric AKI. The complement system has a crucial role in the pathogenesis of atypical hemolytic uremic syndrome (aHUS) and eculizumab (ECZ) was approved as standard of care for its treatment. The two widely characterized forms of infection-associated HUS are Shiga toxin-producing E. coli (STEC)-HUS and Streptococcus pneumoniae-associated (SP)-HUS. Extrarenal manifestations such as central nervous system (CNS) involvement occur approximately in 20% of the cases and are accompanied by higher mortality. Abnormalities of the alternative complement pathway may also contribute to the development of both STEC-HUS and SP-HUS, offering a potential treatment option for complement C5 inhibition. Beyond best supportive care as standard therapeutic approach, ECZ has been successfully used in both STEC-HUS and SP-HUS patients.<\/jats:p>\n                    <jats:p>We provide further support that early use of ECZ for infection-associated HUS with severe clinical manifestation and abnormal complement-activation profile may be an effective therapeutic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report on three children (median age: 2\u00a0years, range: 2\u201310\u00a0years) diagnosed with infection-associated HUS treated with complement C5-inhibitor ECZ. All three patients were treated with ECZ and had excellent outcome. We retrospectively analyzed the clinical course, laboratory data and outcome of children with infection-associated HUS treated with ECZ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In accordance with previous observations ECZ is an efficacious therapeutic choice in severe HUS patients with multiorgan involvement. A detailed complement activation profile, especially sC5b-9, is useful to indicate ECZ administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-025-05546-3","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T23:24:58Z","timestamp":1741649098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of complement C5-inhibitor eculizumab in patients with infection-associated hemolytic uremic syndrome \u2013 a case-series report"],"prefix":"10.1186","volume":"25","author":[{"given":"Petra","family":"Varga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Bir\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Berkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erzs\u00e9bet","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edit","family":"Szikszay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Proh\u00e1szka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"4","key":"5546_CR1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1681\/ASN.2004100861","volume":"16","author":"M Noris","year":"2005","unstructured":"Noris M, Remuzzi G. Hemolytic Uremic Syndrome. J Am Soc Nephrol. 2005;16(4):1035\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"5546_CR2","doi-asserted-by":"publisher","unstructured":"Sheerin, N. S.; Glover, E. Haemolytic Uremic Syndrome: Diagnosis and Management. 2019;F1000Res 8, F1000 Faculty Rev-1690. https:\/\/doi.org\/10.12688\/f1000research.19957.1.","DOI":"10.12688\/f1000research.19957.1"},{"issue":"10","key":"5546_CR3","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1086\/644621","volume":"49","author":"LH Gould","year":"2009","unstructured":"Gould LH, Demma L, Jones TF, Hurd S, Vugia DJ, Smith K, Shiferaw B, Segler S, Palmer A, Zansky S, Griffin PM. Hemolytic uremic syndrome and death in persons with escherichia Coli O157:H7 infection, foodborne diseases active surveillance Network Sites, 2000\u20132006. Clin Infect Dis. 2009;49(10):1480\u20135. https:\/\/doi.org\/10.1086\/644621.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"5546_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nrneph.2012.196","volume":"8","author":"H Trachtman","year":"2012","unstructured":"Trachtman H, Austin C, Lewinski M, Stahl RAK. Renal and neurological involvement in typical shiga toxin-associated HUS. Nat Rev Nephrol. 2012;8(11):658\u201369. https:\/\/doi.org\/10.1038\/nrneph.2012.196.","journal-title":"Nat Rev Nephrol"},{"key":"5546_CR5","doi-asserted-by":"publisher","unstructured":"Loos S, Aulbert W, Hoppe B, Ahlenstiel-Grunow T, Kranz B, Wahl C, Staude H, Humberg A, Benz K, Krause M, Pohl M, Liebau MC, Schild R, Lemke J, Beringer O, M\u00fcller D, H\u00e4rtel C, Wigger M, Vester U, Konrad M, Haffner D, Pape L, Oh J, Kemper MJ. Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. Coli O104:H4. Clin Infect Dis. 2017;64(12),1637\u20131643. https:\/\/doi.org\/10.1093\/cid\/cix218.","DOI":"10.1093\/cid\/cix218"},{"key":"5546_CR6","doi-asserted-by":"publisher","unstructured":"Rosales A, Hofer J, Zimmerhackl L.-B, Jungraithmayr TC, Riedl M, Giner T, Strasak A. Orth-H\u00f6ller D, W\u00fcrzner R, Karch H, German-Austrian HUS Study Group. Need for Long-Term Follow-up in Enterohemorrhagic Escherichia Coli-Associated Hemolytic Uremic Syndrome Due to Late-Emerging Sequelae. Clin Infect Dis. 2012;54(10),1413\u20131421. https:\/\/doi.org\/10.1093\/cid\/cis196.","DOI":"10.1093\/cid\/cis196"},{"issue":"9","key":"5546_CR7","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00467-019-04342-3","volume":"35","author":"RR Scobell","year":"2020","unstructured":"Scobell RR, Kaplan BS, Copelovitch L. New insights into the pathogenesis of streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol. 2020;35(9):1585\u201391. https:\/\/doi.org\/10.1007\/s00467-019-04342-3.","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"5546_CR8","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00467-007-0518-y","volume":"23","author":"L Copelovitch","year":"2008","unstructured":"Copelovitch L, Kaplan BS. Streptococcus Pneumoniae-Associated Hemolytic Uremic Syndrome. Pediatr Nephrol. 2008;23(11):1951\u20136. https:\/\/doi.org\/10.1007\/s00467-007-0518-y.","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"5546_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/j.1440-1754.2009.01603.x","volume":"45","author":"C Prestidge","year":"2009","unstructured":"Prestidge C, Ten WW. Years of pneumococcal-associated haemolytic uraemic syndrome in New Zealand children. J Paediatr Child Health. 2009;45(12):731\u20135. https:\/\/doi.org\/10.1111\/j.1440-1754.2009.01603.x.","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"5546_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","volume":"106","author":"CM Nester","year":"2024","unstructured":"Nester CM, Feldman DL, Burwick R, Cataland S, Chaturvedi S, Cook HT, Cuker A, Dixon BP, Fakhouri F, Hingorani SR, Java A, Van De Kar NCAJ, Kavanagh D, Leung N, Licht C, Noris M, O\u2019Shaughnessy MM, Parikh SV, Peyandi F, Remuzzi G, Smith RJH, Sperati CJ, Waldman M, Walker P, Vivarelli M. An expert discussion on the atypical hemolytic uremic syndrome nomenclature\u2014identifying a road map to precision: a report of a national kidney foundation working group. Kidney Int. 2024;106(3):326\u201336. https:\/\/doi.org\/10.1016\/j.kint.2024.05.021.","journal-title":"Kidney Int"},{"issue":"23","key":"5546_CR11","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981.PMID:23738544.LichtC","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, N\u00fcrnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381. https:\/\/doi.org\/10.1056\/NEJMoa1208981.PMID:23738544.LichtC.","journal-title":"N Engl J Med"},{"issue":"9","key":"5546_CR12","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00467-018-4025-0","volume":"34","author":"PR Walsh","year":"2019","unstructured":"Walsh PR, Johnson S. Eculizumab in the Treatment of Shiga Toxin Haemolytic Uraemic Syndrome. Pediatr Nephrol. 2019;34(9):1485\u201392. https:\/\/doi.org\/10.1007\/s00467-018-4025-0.","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"5546_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27913","volume":"66","author":"U Mahat","year":"2019","unstructured":"Mahat U, Matar RB, Rotz SJ. Use of complement monoclonal antibody eculizumab in shiga toxin producing escherichia coli associated hemolytic uremic syndrome: a review of current evidence. Pediatr Blood Cancer. 2019;66(11): e27913. https:\/\/doi.org\/10.1002\/pbc.27913.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"5546_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5863\/1551-6776-27.1.90","volume":"27","author":"B Weber","year":"2022","unstructured":"Weber B, Chan D, Hammer S. Eculizumab use in a temporarily dialysis-dependent patient with shiga toxin-producing escherichia coli hemolytic uremic syndrome with neurological complications. J Pediatr Pharmacol Ther. 2022;27(1):90\u20135. https:\/\/doi.org\/10.5863\/1551-6776-27.1.90.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"12","key":"5546_CR15","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/ndt\/gfz158","volume":"35","author":"C Monet-Didailler","year":"2020","unstructured":"Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, Allard L, Delmas Y, Contin-Bordes C, Brissaud O, Llanas B, Harambat J. Outcome of children with Shiga Toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrol Dial Transplant. 2020;35(12):2147\u201353. https:\/\/doi.org\/10.1093\/ndt\/gfz158.","journal-title":"Nephrol Dial Transplant"},{"issue":"26","key":"5546_CR16","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMc1100859","volume":"364","author":"A-L Lapeyraque","year":"2011","unstructured":"Lapeyraque A-L, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont M-J, Le Deist F, Niaudet P, Schaefer F. Eculizumab in Severe Shiga-Toxin-Associated HUS. N Engl J Med. 2011;364(26):2561\u20133. https:\/\/doi.org\/10.1056\/NEJMc1100859.","journal-title":"N Engl J Med"},{"issue":"9","key":"5546_CR17","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1681\/ASN.0000000000000182","volume":"34","author":"A Garnier","year":"2023","unstructured":"Garnier A, Brochard K, Kwon T, Sellier-Leclerc A-L, Lahoche A, Launay EA, Nobili F, Caillez M, Taque S, Harambat J, Michel-Bourdat G, Guigonis V, Fila M, Cloarec S, Djamal-Dine D, de Parscaux L, Allard L, Salomon R, Ulinski T, Fr\u00e9meaux-Bacchi V, Morin C, Olivier-Abbal P, Colineaux H, Auriol F, Arnaud C, Kieffer I, Brusq C. Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized. Placebo-Controlled Trial J Am Soc Nephrol. 2023;34(9):1561\u201373. https:\/\/doi.org\/10.1681\/ASN.0000000000000182.","journal-title":"Placebo-Controlled Trial J Am Soc Nephrol"},{"issue":"1","key":"5546_CR18","first-page":"115","volume":"35","author":"G Sinkovits","year":"2014","unstructured":"Sinkovits G, Proh\u00e1szka Z. Update on the role of the complement system in the pathogenesis of thrombotic microangiopathies. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2014;35(1):115\u201322.","journal-title":"Pril (Makedon Akad Nauk Umet Odd Med Nauki)"},{"issue":"9","key":"5546_CR19","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1093\/ndt\/gft198","volume":"28","author":"A Szil\u00e1gyi","year":"2013","unstructured":"Szil\u00e1gyi A, Kiss N, Bereczki C, T\u00e1losi G, R\u00e1cz K, T\u00fari S, Gy\u00f6rke Z, Simon E, Horv\u00e1th E, Kelen K, Reusz GS, Szab\u00f3 AJ, Tulassay T, Proh\u00e1szka Z. The role of complement in streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant. 2013;28(9):2237\u201345. https:\/\/doi.org\/10.1093\/ndt\/gft198.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"5546_CR20","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179\u201384. https:\/\/doi.org\/10.1159\/000339789.","journal-title":"Nephron Clin Pract"},{"issue":"5","key":"5546_CR21","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00467-021-04952-w","volume":"36","author":"J Holle","year":"2021","unstructured":"Holle J, Habbig S, Gratopp A, Mauritsch A, M\u00fcller D, Thumfart J. Complement activation in children with streptococcus pneumoniae associated hemolytic uremic syndrome. Pediatr Nephrol. 2021;36(5):1311\u20135. https:\/\/doi.org\/10.1007\/s00467-021-04952-w.","journal-title":"Pediatr Nephrol"},{"key":"5546_CR22","doi-asserted-by":"publisher","unstructured":"Igarashi T, Ito S, Sako M, Saitoh A, Hataya H, Mizuguchi M, Morishima T, Ohnishi K, Kawamura N, Kitayama H, Ashida A, Kaname S, Taneichi H, Tang J, Ohnishi M. Study group for establishing guidelines for the diagnosis and therapy of hemolytic uremic syndrome. Guidelines for the Management and Investigation of Hemolytic Uremic Syndrome. Clin Exp Nephrol. 2014;18(4),525\u2013557. https:\/\/doi.org\/10.1007\/s10157-014-0995-9.","DOI":"10.1007\/s10157-014-0995-9"},{"key":"5546_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/asheducation.V2012.1.617.3798924","volume":"1","author":"CM Nester","year":"2012","unstructured":"Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology. 2012;1:617\u201325. https:\/\/doi.org\/10.1182\/asheducation.V2012.1.617.3798924.","journal-title":"Hematology"},{"issue":"17","key":"5546_CR24","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676\u201387. https:\/\/doi.org\/10.1056\/NEJMra0902814.","journal-title":"N Engl J Med"},{"issue":"6","key":"5546_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.radcr.2021.02.059","volume":"16","author":"J Musa","year":"2021","unstructured":"Musa J, Rahman M, Guy A, Kola E, Guy A, Hyseni F, Cobo A, Saliaj K, Bushati F, Ahmetgjekaj I. Artery of percheron infarction: a case report and literature review. Radiol Case Rep. 2021;16(6):1271\u20135. https:\/\/doi.org\/10.1016\/j.radcr.2021.02.059.","journal-title":"Radiol Case Rep"},{"issue":"2","key":"5546_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0883073808322672","volume":"24","author":"SE Bain","year":"2009","unstructured":"Bain SE, Hsieh DT, Vezina LG, Chang T. Bilateral paramedian thalamic and mesencephalic infarcts in a newborn due to occlusion of the artery of percheron. J Child Neurol. 2009;24(2):219\u201323. https:\/\/doi.org\/10.1177\/0883073808322672.","journal-title":"J Child Neurol"},{"issue":"8","key":"5546_CR27","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00467-018-3903-9","volume":"33","author":"L Percheron","year":"2018","unstructured":"Percheron L, Gramada R, Tellier S, Salomon R, Harambat J, Llanas B, Fila M, Allain-Launay E, Lapeyraque A-L, Leroy V, Adra A-L, B\u00e9rard E, Bourdat-Michel G, Chehade H, Eckart P, Merieau E, Pi\u00e8trement C, Sellier-Leclerc A-L, Fr\u00e9meaux-Bacchi V, Dimeglio C, Garnier A. Eculizumab Treatment in Severe Pediatric STEC-HUS: A Multicenter Retrospective Study. Pediatr Nephrol. 2018;33(8):1385\u201394. https:\/\/doi.org\/10.1007\/s00467-018-3903-9.","journal-title":"Pediatr Nephrol"},{"issue":"24","key":"5546_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001000","volume":"94","author":"L Pape","year":"2016","unstructured":"Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (Baltimore). 2016;94(24): e1000. https:\/\/doi.org\/10.1097\/MD.0000000000001000.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"5546_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00467-023-06102-w","volume":"39","author":"DM Wildes","year":"2024","unstructured":"Wildes DM, Harvey S, Costigan CS, Sweeney C, Twomey \u00c9, Awan A, Gorman KM. Eculizumab in STEC-HUS: A Paradigm Shift in the Management of Pediatric Patients with Neurological Involvement. Pediatr Nephrol. 2024;39(1):315\u201324. https:\/\/doi.org\/10.1007\/s00467-023-06102-w.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"5546_CR30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.mehy.2013.05.030","volume":"81","author":"RD Gilbert","year":"2013","unstructured":"Gilbert RD, Nagra A, Haq MR. Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to streptococcus pneumoniae? Med Hypotheses. 2013;81(3):400\u20133. https:\/\/doi.org\/10.1016\/j.mehy.2013.05.030.","journal-title":"Med Hypotheses"},{"issue":"12","key":"5546_CR31","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1007\/s00467-023-06037-2","volume":"38","author":"P Konop\u00e1sek","year":"2023","unstructured":"Konop\u00e1sek P, Zieg J. Eculizumab use in patients with pneumococcal-associated hemolytic uremic syndrome and kidney outcomes. Pediatr Nephrol. 2023;38(12):4209\u201315. https:\/\/doi.org\/10.1007\/s00467-023-06037-2.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"5546_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/pathogens10060727","volume":"10","author":"HS Agarwal","year":"2021","unstructured":"Agarwal HS, Latifi SQ. Streptococcus pneumoniae-associated hemolytic uremic syndrome in the Era of pneumococcal vaccine. Pathogens. 2021;10(6):727. https:\/\/doi.org\/10.3390\/pathogens10060727.","journal-title":"Pathogens"},{"key":"5546_CR33","unstructured":"Soliris (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS). Drugs.com. https:\/\/www.drugs.com\/newdrugs\/soliris-eculizumab-approved-fda-all-patients-atypical-hemolytic-uremic-syndrome-ahus-2872.html. Accessed 2024\u201308\u201317."},{"key":"5546_CR34","unstructured":"European Medicines Agency - Human medicines - EU\/3\/09\/653. https:\/\/web.archive.org\/web\/20170923013346\/http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages%2Fmedicines%2Fhuman%2Forphans%2F2009%2F11%2Fhuman_orphan_000657.jsp&mid=WC0b01ac058001d12b (accessed 2024\u201308\u201317)."},{"issue":"2","key":"5546_CR35","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00431-021-04200-1","volume":"181","author":"C Costigan","year":"2022","unstructured":"Costigan C, Raftery T, Carroll AG, Wildes D, Reynolds C, Cunney R, Dolan N, Drew RJ, Lynch BJ, O\u2019Rourke DJ, Stack M, Sweeney C, Shahwan A, Twomey E, Waldron M, Riordan M, Awan A, Gorman KM. Neurological Involvement in Children with Hemolytic Uremic Syndrome. Eur J Pediatr. 2022;181(2):501\u201312. https:\/\/doi.org\/10.1007\/s00431-021-04200-1.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"5546_CR36","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu Z-H, Mej\u00eda-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders J-SF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Floege J. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1\u2013276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","journal-title":"Kidney Int"},{"key":"5546_CR37","doi-asserted-by":"publisher","unstructured":"Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev. 2010;Oct;23(4):740\u201380. https:\/\/doi.org\/10.1128\/CMR.00048-09. PMID: 20930072; PMCID: PMC2952982.","DOI":"10.1128\/CMR.00048-09"},{"issue":"3","key":"5546_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00431-017-3077-7","volume":"177","author":"W Keenswijk","year":"2018","unstructured":"Keenswijk W, Raes A, Vande Walle J. Is eculizumab efficacious in shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Eur J Pediatr. 2018;177(3):311\u20138. https:\/\/doi.org\/10.1007\/s00431-017-3077-7.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"5546_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","volume":"29","author":"E Benamu","year":"2016","unstructured":"Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29(4):319\u201329. https:\/\/doi.org\/10.1097\/QCO.0000000000000279.","journal-title":"Curr Opin Infect Dis"},{"key":"5546_CR40","doi-asserted-by":"publisher","unstructured":"Sonata Jodele, Christopher E. Dandoy, Adam Lane, Benjamin L. Laskin, Ashley Teusink-Cross, Kasiani C. Myers, Gregory Wallace, Adam Nelson, Jack Bleesing, Ranjit S. Chima, Russel Hirsch, Thomas D. Ryan, Stefanie Benoit, Kana Mizuno, Mikako Warren, Stella M. Davies; Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020;135(13):1049\u20131057. https:\/\/doi.org\/10.1182\/blood.2019004218","DOI":"10.1182\/blood.2019004218"},{"key":"5546_CR41","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/cc7875","volume":"13","author":"R Osawa","year":"2009","unstructured":"Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009;13:R68. https:\/\/doi.org\/10.1186\/cc7875.","journal-title":"Crit Care"},{"issue":"17","key":"5546_CR42","doi-asserted-by":"publisher","first-page":"13041","DOI":"10.3390\/ijms241713041","volume":"24","author":"D Turudic","year":"2023","unstructured":"Turudic D, Pokrajac D, Tasic V, Kasumovic D, Prohaszka Z, Milosevic D. The Rationale of Complement Blockade of the MCPggaac haplotype following atypical hemolytic uremic syndrome of three southeastern european countries with a literature review. Int J Mol Sci. 2023;24(17):13041. https:\/\/doi.org\/10.3390\/ijms241713041.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5546_CR43","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/cei.12890","volume":"187","author":"C Wehling","year":"2017","unstructured":"Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, T\u00f6nshoff B, B\u00fcscher R, Fehrenbach H, G\u00f6k \u00d6-N, Kirschfink M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol. 2017;187(2):304\u201315. https:\/\/doi.org\/10.1111\/cei.12890.","journal-title":"Clin Exp Immunol"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05546-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-05546-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05546-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T11:10:31Z","timestamp":1741691431000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-025-05546-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5546"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-05546-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5389564\/v1","asserted-by":"object"}]},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Scientific and Research Ethics Committee of the University of Debrecen under the registration number of 6879\u20132024 (DE KK RKEB\/IKEB). Patients were enrolled in accordance with the Declaration of Helsinki.During anonymous data management, a general patient information sheet and an informed consent form were used. No additional intervention was performed, only the necessary and usual therapeutic and diagnostic methods were used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of identifying images or other personal or clinical details was obtained from the parents of all the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}